226 related articles for article (PubMed ID: 27654852)
1. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
Qazilbash MH; Wieder E; Thall PF; Wang X; Rios R; Lu S; Kanodia S; Ruisaard KE; Giralt SA; Estey EH; Cortes J; Komanduri KV; Clise-Dwyer K; Alatrash G; Ma Q; Champlin RE; Molldrem JJ
Leukemia; 2017 Mar; 31(3):697-704. PubMed ID: 27654852
[TBL] [Abstract][Full Text] [Related]
2. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
3. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
5. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
Lacey SF; La Rosa C; Kaltcheva T; Srivastava T; Seidel A; Zhou W; Rawal R; Hagen K; Krishnan A; Longmate J; Andersson HA; St John L; Bhatia R; Pullarkat V; Forman SJ; Cooper LJ; Molldrem J; Diamond DJ
Blood; 2011 Aug; 118(8):2159-69. PubMed ID: 21719601
[TBL] [Abstract][Full Text] [Related]
6. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.
Kanodia S; Wieder E; Lu S; Talpaz M; Alatrash G; Clise-Dwyer K; Molldrem JJ
PLoS One; 2010 Jul; 5(7):e11770. PubMed ID: 20668669
[TBL] [Abstract][Full Text] [Related]
7. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy.
Rezvani K; Yong AS; Mielke S; Savani BN; Jafarpour B; Eniafe R; Le RQ; Musse L; Boss C; Childs R; John Barrett A
Cancer Immunol Immunother; 2012 Jul; 61(7):1125-36. PubMed ID: 22198310
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
9. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.
Sergeeva A; Alatrash G; He H; Ruisaard K; Lu S; Wygant J; McIntyre BW; Ma Q; Li D; St John L; Clise-Dwyer K; Molldrem JJ
Blood; 2011 Apr; 117(16):4262-72. PubMed ID: 21296998
[TBL] [Abstract][Full Text] [Related]
10. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
[TBL] [Abstract][Full Text] [Related]
12. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
Blood; 2008 Jan; 111(1):236-42. PubMed ID: 17875804
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil granule proteins as targets of leukemia-specific immune responses.
Barrett J; Rezvani K
Curr Opin Hematol; 2006 Jan; 13(1):15-20. PubMed ID: 16319682
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem JJ; Lee PP; Kant S; Wieder E; Jiang W; Lu S; Wang C; Davis MM
J Clin Invest; 2003 Mar; 111(5):639-47. PubMed ID: 12618518
[TBL] [Abstract][Full Text] [Related]
15. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
Front Immunol; 2018; 9():3153. PubMed ID: 30713535
[TBL] [Abstract][Full Text] [Related]
16. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.
Fujiwara H; El Ouriaghli F; Grube M; Price DA; Rezvani K; Gostick E; Sconocchia G; Melenhorst J; Hensel N; Douek DC; Barrett AJ
Blood; 2004 Apr; 103(8):3076-83. PubMed ID: 15070688
[TBL] [Abstract][Full Text] [Related]
17. PR1 vaccination in myeloid malignancies.
Rezvani K
Expert Rev Vaccines; 2008 Sep; 7(7):867-75. PubMed ID: 18767937
[TBL] [Abstract][Full Text] [Related]
18. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
[TBL] [Abstract][Full Text] [Related]
19. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
